Novartis signs RNA deal with China's Abogen worth up to $7.8 billion
Novartis pays $575 million up front for an exclusive license to ABO2203 and options on other programs.
Intelligence
The parties
Activity
Novartis pays $575 million up front for an exclusive license to ABO2203 and options on other programs.
Intelligence
Activity